1BryantRV, WinerS, TravisSP,et al.Systematic review: histological remission in inflammatory bowel disease. Is 'complete’ remission the new treatment paradigm? An IOIBD initiative[J]. J Crohns Colitis, 2014,8(12):1582-1597. DOI: 10.1016/j.crohns.2014.08.011.
2SwanNC, GeogheganJG, O′DonoghueDP, et al.Fulminant colitis in inflammatory bowel disease: detailed pathologic and clinical analysis[J]. Dis Colon Rectum, 1998, 41(12):1511-1515.
3RiddellR, JainD. Lewin, Weinstein and Riddell′s gastrointestinal pathology and its clinical implications[M]. 2nd ed. Philadelphia: Wolters Kluwer/ Lippincott Williams & Wilkins, 2014:12.
4KiesslichR, FritschJ, HoltmannM,et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis[J]. Gastroenterology, 2003, 124(4):880-888. DOI: 10.1053/gast.2003.50146.
5LaineL, KaltenbachT, BarkunA,et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease[J]. Gastroenterology, 2015,148(3):639-651. DOI: 10.1053/j.gastro.2015.01.031.
7BessissowT, LemmensB, FerranteM, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing[J]. Am J Gastroenterol, 2012,107(11):1684-1692. DOI: 10.1038/ajg.2012.301.
8ParianA, LazarevM. Who and how to screen for cancer in at-risk inflammatory bowel disease patients[J]. Expert Rev Gastroenterol Hepatol, 2015,9(6):731-746. DOI: 10.1586/17474124.2015.1003208.
